About Adaptimmune Therapeutics Plc

Adaptimmune Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

At the moment the company generates 2M USD in revenues.

On its last earning announcement, the company reported a loss of -1.38$ per share.

The book value per share is 1.40$

Adaptimmune Therapeutics Plc website


Financials

Revenue USD Gross Margin Operating Income Operating Margin Net Income Earnings Per Share Dividends Payout Ratio Shares Book Value Per Share Operating Cash Flow Cap Spending Free Cash Flow
2M - -142M -138.40% -144M -1.38 - - 104M 1.40 -132M -3M -134M